Search Results for: Pharma 40 A New Initiative
Articles
Catalent Becomes First CDMO to Join Pharmaceutical Supply Chain Initiative December 8, 2016
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health...Catalent to Open New Clinical Supply Facility in Japan January 26, 2016
Catalent Pharma Solutions recently announced that it is to introduce clinical supply services at its 200,000-sq-ft cGMP facility in Kakegawa,...Dow Corning Launches New Portfolio of Topical Ingredients to Help Customers Advance Innovations in Consumer Health Care Applications November 2, 2015
Dow Corning, a global leader in silicones, silicon-based technology and innovation, unveiled at the American Association of Pharmaceutical Scientists’ (AAPS)...PDL BioPharma Acquires Portion of Royalty Interest for $65.6 Million November 10, 2014
PDL BioPharma recently announced it has acquired a portion of the University of Michigan's worldwide royalty interest in Cerdelga (eliglustat)...ENA Respiratory Announces FDA IND Clearance for First-in-Class Antiviral Innate Immunomodulator April 29, 2024
ENA Respiratory recently announced the US FDA has issued a "safe to proceed" notice for its investigational new drug (IND)...Bio-Rad & Allegheny Health Network Cancer Institute Collaborate to Advance Personalized Monitoring of Solid Tumor Cancers With Droplet Digital PCR April 8, 2024
Bio-Rad Laboratories, Inc. recently announced a collaboration with Allegheny Health Network (AHN) aimed to generate clinical evidence across a range...THERAPEUTIC FOCUS - Sarilumab Approval for Polymyalgia Rheumatica Highlights Enduring Unmet Medical Needs March 28, 2024
David A. Katz, PhD, and Robert Jacks, MBA, MSE, say a new, effective treatment option is now available, promotion of the drug will increase disease awareness, and the success encourages others in the industry to continue and expand their PMR research. However, the proportion of patients who can benefit from the drug is limited, and significant unmet needs remain for all persons suffering from PMR.
Vetter Contributes to Commercial Launches of Eight Customer Products in 2023 February 14, 2024
New molecules candidates brought to Vetter in the clinic receive strategic counsel and experienced support to guide their path to market and beyond….
SPECIAL ROUNDTABLE - Leadership Panel: 4 Trends That Will Have the Most Impact on Drug Development in 2024 January 26, 2024
Contributor Cindy H. Dubin asked some of today’s life science leaders what they expect will have the greatest impact on drug development in 2024 and beyond.
Coya Therapeutics & Dr. Reddy’s Laboratories Enter Development & Commercialization Agreement for ALS Treatment December 11, 2023
Dr. Reddy’s Laboratories SA and Coya Therapeutics, Inc. recently announced they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for….
Hovione Expands Nasal Drug Delivery Capabilities With Development of Nasal Powder Delivery Device Technology in Collaboration With IDC November 29, 2023
Hovione and Industrial Design Consultancy (IDC) have entered into a joint development of an innovative nasal powder delivery device technology supporting local, systemic, and nose-to-brain drug delivery….
Anavex’s Phase 2b/3 Trial of Blarcamesine in Patients With Alzheimer’s Disease Shows Robust Clinical Efficacy & Slows Neurodegeneration September 14, 2023
Anavex Life Sciences Corp. recently announced that a follow-on analysis of the landmark Phase 2b/3 study to treat early Alzheimer’s...BioCorRx Submits Expanded Access Treatment Protocol to FDA for Implantable Biodegradable Naltrexone Pellet for Opioid Use Disorder Treatment August 15, 2023
Company hopes in 30 days to begin making its drug candidate available to help patients and address public health crisis….
MARKET TRENDS - The Year of Resilience & Flexibility: Six Smart Ways CDMOs Are Preparing for 2023 April 3, 2023
Carsten Press says with biopharma businesses weathering one unexpected shift after another, it’s no surprise these organizations are looking to their partner networks for one thing above all: the flexibility they need to maximize their own business resilience.
MARKET REPORT - Survey Suggests Global Innovation to Recover Much More Quickly Than Expected in 2023 February 9, 2023
After a brief fall in 2022 to a score of 6.5 – the first decline since its inception in 2018 – the index has surged to a record score of 7.4. This sudden recovery in scores over a little more than 8 months bodes extremely well for device and packaging manufacturers in the year ahead, suggesting a strong global recovery in industry outlook and confidence.
Biogen & Denali Therapeutics Announce Initiation of Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated With LRRK2 Pathogenic Mutations October 3, 2022
Biogen Inc. and Denali Therapeutics Inc. recently announced dosing has commenced in the global Phase 3 LIGHTHOUSE study to evaluate...SPECIAL FEATURE - Injection Devices: Three Trends Influencing Development & Delivery September 1, 2022
Contributor Cindy H. Dubin showcases in this annual feature how various innovative device manufacturers are addressing the current trends in their injection designs.
Mogrify & Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss July 5, 2022
Mogrify Limited and Astellas Pharma Inc. recently announced they have executed a collaborative research agreement on in vivo regenerative medicine approaches to….
CLINICAL TRIALS SOLUTIONS - Cracking Down on the Rising Costs of Drug Development: How Pinpointing the Complexity of Individual Patients Can Improve Success Rates June 1, 2022
Dominique Demolle, PhD, and Erica Smith, PhD, say taking a more holistic, patient-centric approach by considering patients’ individual psychology, perceptions, and beliefs provides drug developers the opportunity to quantify these interpersonal differences between patients and address this source of variability in data analysis and interpretation.
Denali Therapeutics & Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease May 31, 2022
Denali Therapeutics Inc. and Biogen Inc. recently announced that dosing has commenced in the global Phase 2b LUMA study to...
